<?xml version='1.0' encoding='utf-8'?>
<document id="29550976"><sentence text="Development of a simultaneous LC-MS/MS method to predict in vivo drug-drug interaction in mice." /><sentence text="Cocktail substrates are useful in investigating drug-drug interactions (DDI) that can rapidly identify the cytochrome P450 (CYP) isoforms that interact with test drugs" /><sentence text=" In this study, we developed and validated five probe drugs for CYP1A, CYP2B, CYP2C, CYP2D, and CYP3A using LC-MS/MS to determine CYP activities in mice" /><sentence text=" The five probe substrates were caffeine (2 mg/kg), bupropion (30 mg/kg), omeprazole (4 mg/kg), dextromethorphan (40 mg/kg), and midazolam (2 mg/kg) for CYP1A, CYP2B, CYP2C, CYP2D, and CYP3A, respectively"><entity charOffset="32-40" id="DDI-PubMed.29550976.s4.e0" text="caffeine" /><entity charOffset="52-61" id="DDI-PubMed.29550976.s4.e1" text="bupropion" /><entity charOffset="74-84" id="DDI-PubMed.29550976.s4.e2" text="omeprazole" /><entity charOffset="96-112" id="DDI-PubMed.29550976.s4.e3" text="dextromethorphan" /><entity charOffset="129-138" id="DDI-PubMed.29550976.s4.e4" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.29550976.s4.e0" e2="DDI-PubMed.29550976.s4.e0" /><pair ddi="false" e1="DDI-PubMed.29550976.s4.e0" e2="DDI-PubMed.29550976.s4.e1" /><pair ddi="false" e1="DDI-PubMed.29550976.s4.e0" e2="DDI-PubMed.29550976.s4.e2" /><pair ddi="false" e1="DDI-PubMed.29550976.s4.e0" e2="DDI-PubMed.29550976.s4.e3" /><pair ddi="false" e1="DDI-PubMed.29550976.s4.e0" e2="DDI-PubMed.29550976.s4.e4" /><pair ddi="false" e1="DDI-PubMed.29550976.s4.e1" e2="DDI-PubMed.29550976.s4.e1" /><pair ddi="false" e1="DDI-PubMed.29550976.s4.e1" e2="DDI-PubMed.29550976.s4.e2" /><pair ddi="false" e1="DDI-PubMed.29550976.s4.e1" e2="DDI-PubMed.29550976.s4.e3" /><pair ddi="false" e1="DDI-PubMed.29550976.s4.e1" e2="DDI-PubMed.29550976.s4.e4" /><pair ddi="false" e1="DDI-PubMed.29550976.s4.e2" e2="DDI-PubMed.29550976.s4.e2" /><pair ddi="false" e1="DDI-PubMed.29550976.s4.e2" e2="DDI-PubMed.29550976.s4.e3" /><pair ddi="false" e1="DDI-PubMed.29550976.s4.e2" e2="DDI-PubMed.29550976.s4.e4" /><pair ddi="false" e1="DDI-PubMed.29550976.s4.e3" e2="DDI-PubMed.29550976.s4.e3" /><pair ddi="false" e1="DDI-PubMed.29550976.s4.e3" e2="DDI-PubMed.29550976.s4.e4" /></sentence><sentence text=" The cocktail substrates were orally administered to male 5-week-old ICR mice over 0-240 min" /><sentence text=" The analytical method was validated; it showed high selectivity, linearity, and acceptable accuracy" /><sentence text=" We confirmed the lack of interaction of this cocktail in the control state (no effect of CYP inducer or inhibitor) and suggested AUCratio (metabolite/substrate) as a unit to evaluate DDI in vivo" /><sentence text=" In addition, the cocktail assay was applied for the determination of pharmacokinetic parameters against phenobarbital as a selective CYP2B inducer and ketoconazole as a strong CYP3A inhibitor"><entity charOffset="152-164" id="DDI-PubMed.29550976.s8.e0" text="ketoconazole" /></sentence><sentence text=" The concentration of cocktail substrates and the LC-MS/MS method were optimized" /><sentence text=" In conclusion, we developed a simultaneous and comprehensive analysis system for predicting potential DDI in mice" /><sentence text="" /></document>